Developer of next-generation controllable cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer. The company's therapies are based on pharmacologic operating systems that provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under the control of the treating physician using simple, safe, orally active, marketed drugs, enabling doctors to improve on the current generation of cell therapies.